MIRA Pharmaceuticals, Inc. MIRA PHARMA
Company Overview
MIRA Pharmaceuticals, Inc. operates as a pre-clinical-stage pharmaceutical development company with two neuroscience programs targeting a range of neurologic and neuropsychiatric disorders. The company holds exclusive U.S., Canadian, and Mexican rights for Ketamir-2, a next-generation oral NMDA receptor modulator, that has completed a Phase 1 clinical trial. It also offers oral pharmaceutical marijuana, MIRA-55, is under investigation for treating adult patients suffering from anxiety and cognitive decline, often associated with early-stage dementia; and SKNY-1, that is in preclinical stage for obesity and nicotine dependence. The company was formerly known as MIRA1a Therapeutics, Inc. MIRA Pharmaceuticals, Inc. was incorporated in 2020 and is based in Miami, Florida.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -47.93% |
| 6 Months: | -33.12% |
| 3 Months: | -22.42% |
| 1 Month: | +4.84% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)48.59 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 56.9% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | MIRA MIRA Pharmaceuticals, Inc. PHARMA | 0.78 | -0.64 | $32.78M | 0.00% | -100.98% | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -1.48M | -2.42M | -1.81M | -1.34M | -1.27M | -3.59M | -1.72M | -1.69M | -2.04M | -1.78M | -1.54M | -1.14M | -1.15M |
| Diluted EPS | - | -0.19 | -0.14 | -0.10 | -0.10 | -0.26 | -0.15 | -0.11 | -0.14 | -0.11 | -0.09 | -1.18 | -0.03 |
| R&D Expense | - | - | 714.97K | 271.61K | -101.02K | 1.02M | 762.28K | 614.46K | 1.07M | 314.40K | 496.20K | 412.64K | 524.78K |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 7.05M | 8.53M | 8.02M | 10.49M |
| Operating Income | - | -7.05M | -8.53M | -8.02M | -10.49M |
| EBITDA | - | -7.05M | -8.53M | -8.02M | -10.49M |
| Interest Expense | 24.37K | 10.25K | 3.46M | - | - |
| Pretax Income | - | -7.06M | -11.98M | -7.85M | -10.44M |
| Tax Provision | - | - | - | - | - |
| Net Income | - | -7.06M | -11.98M | -7.85M | -10.44M |
| Diluted EPS | - | -0.40 | -0.85 | -0.51 | -1.35 |
| R&D Expense | - | 2.35M | 1.57M | 3.31M | 1.72M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 858.07K | 4.93M | 2.92M | 11.09M |
| Total Equity | 2.26M | -596.23K | 4.37M | 2.20M | 10.39M |
| Cash & Equivalents | - | - | - | 2.83M | 6.35M |
| Total Liabilities | - | 1.45M | 558.10K | 723.35K | 702.07K |
| Current Liabilities | - | 1.37M | 558.10K | 723.35K | 702.07K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -5.60M | -4.53M | -5.56M | -4.66M |
| Financing Cash Flow | 3.15M | 8.78M | 3.79M | 8.18M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | 1,183.8% | -273.9% | -357.0% | -100.5% |
| ROCE % | - | 1,376.6% | -194.9% | -364.5% | -101.0% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Vanguard Capital Management LLC | 1.79% | 751.80K | $625.72K |
| 2 | Cross Staff Investments Inc. | 0.86% | 359.40K | $299.13K |
| 3 | Geode Capital Management, LLC | 0.72% | 303.88K | $252.92K |
| 4 | Blackrock Inc. | 0.58% | 244.62K | $203.60K |
| 5 | Vanguard Fiduciary Trust Co | 0.41% | 170.67K | $142.05K |
| 6 | CAPTRUST Financial Advisors | 0.22% | 90.64K | $75.44K |
| 7 | Northern Trust Corporation | 0.16% | 67.73K | $56.38K |
| 8 | First American Bank | 0.14% | 60.00K | $49.94K |
| 9 | Commonwealth Equity Services, LLC | 0.13% | 53.19K | $44.27K |
| 10 | State Street Corporation | 0.12% | 49.10K | $40.87K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for MIRA
Nvidia Stock Price Faces Key Test On AWS Deal, Mira Murati Bet - Coinpedia
<a href="https://news.google.com/rss/articles/CBMiowFBVV95cUxQRWtKRWxpZTN1LU8xZFlmMXpJOXJZc25nWXhCRFNrV0xrUHphSlktRklXYUo1UzJPRE5vY09IZS1rNGs5WkR1UXc2dUsxTjlBZXJ3TXY3UjgzeGJDNjJZUXRjMXdTUmZxbEs1ZFZOV28tM1lrSjA4SnFSUG9Scnk2VzBQSTVnSy1PQndpTl…
MIRA's Two Oral Drug Candidates Finish Dosing in Rats and Dogs - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxQVm5MUVhvOHpBV0cxZHBCOEJfeFZwbVZ2WE11enhQYm9tclR2Y3RSdXctQXZMN3ZjdG9TWEhLNDFHMV9ubDlaMnJQelA5Nll2ZGp4Y0ZhQm9Fa09XTlVQdkxkaFZUQU1oSmxuR1ExZVhySlNGOUhUaDkxYmxWdmdYcWU5ME1UMDNGc1VvdF…
Market Movers | Winners: AEMD, HYFM, FUSE | Losers: GYGY, CALC, MIRA - Trefis
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxONmpZejhMN1plVjVocTU4ZFo2M1c3ajlfbkppWmszcmdQSTZrUG9qS1A0MS1peFlVeVVfZ2RZZXBzSUNjVDUwZ3l2SUtMRjREOEp3THZTRllyV29NMmExZjY0c2h3X09xb2tfNUxDTEtaNjVwVFJBaUJHQ200aldZcENNR21feEhTQmExQ2…
Why Is MIRA Pharmaceuticals Stock Gaining Tuesday? - Benzinga
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxPbkNXWkd0bDY2ekdVYkVjZ2JydVhwLUg4eDZoeDJYSm9BM1dDV2RMcGxaVF9oUm5WRHVudVY5bUFWZDdaR1UyX19LRG9BZnVHVkpnUFozWFN1SzFfekVtQVNjMFYxNjFabWpnTGZobnlhdE1iSFBnZ216a3F5dEpHN2duNHNjQVM1cWw2WV…
Short Interest Alert: Most and least shorted sub-$2B healthcare stocks in Aug 2026 - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiugFBVV95cUxQaTdjUzVtRVY3WVVWYXd4ZzlrYnpmZWlpT0F2bFpiaXhfcndPTGpEU184c1EtR2NnNFAybVNIMXBhbmxRcXdESkZqSW1RXzAxNWpUeHhsZGFkazBQMzlwTUJGbUkzOS1wc2pLSVYwb0JCV0FiY084NWNNNG9ZQjNhNGFranByak9BSkxvUG…
MIRA - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1OQ3ZiRDNNbVBkcTZvci1DOVhxeHlVVTJGWWNaMGtfZFBRNU9WbTNweWhwMWtBZEhNUGppU0h6SzlUdDBBM3c?oc=5" target="_blank">MIRA</a> <font color="#6f6f6f">Finviz</font>…
MIRA — Frequently Asked Questions
What is the current share price of MIRA Pharmaceuticals, Inc. (MIRA)?
As of 2026-09-19 21:16 PDT, MIRA Pharmaceuticals, Inc. (MIRA) trades at $0.78 on NasdaqCM. Its 52-week range is $0.61 to $1.80.
What is the market capitalisation of MIRA?
MIRA Pharmaceuticals, Inc. (MIRA) has a market capitalisation of $32.78M on NasdaqCM.
What is the P/E ratio of MIRA?
MIRA trades at a trailing price-to-earnings (P/E) ratio of -0.64. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 4.29.
Is MIRA a good stock to buy?
This page provides a data-driven analysis of MIRA Pharmaceuticals, Inc. (MIRA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.